nodes	percent_of_prediction	percent_of_DWPC	metapath
Mifepristone—ABCC1—Dactinomycin—sarcoma	0.118	0.147	CbGbCtD
Mifepristone—ABCC1—Mitoxantrone—sarcoma	0.106	0.131	CbGbCtD
Mifepristone—ABCC1—Epirubicin—sarcoma	0.0857	0.106	CbGbCtD
Mifepristone—ABCC1—Vincristine—sarcoma	0.0728	0.0904	CbGbCtD
Mifepristone—ABCC1—Etoposide—sarcoma	0.0667	0.0829	CbGbCtD
Mifepristone—ABCC1—Doxorubicin—sarcoma	0.0455	0.0565	CbGbCtD
Mifepristone—CYP3A7—Vincristine—sarcoma	0.036	0.0447	CbGbCtD
Mifepristone—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.036	0.0447	CbGbCtD
Mifepristone—CYP3A4—Thiotepa—sarcoma	0.0356	0.0442	CbGbCtD
Mifepristone—ABCB1—Dactinomycin—sarcoma	0.0285	0.0354	CbGbCtD
Mifepristone—CYP3A5—Vincristine—sarcoma	0.027	0.0335	CbGbCtD
Mifepristone—ABCB1—Mitoxantrone—sarcoma	0.0255	0.0317	CbGbCtD
Mifepristone—CYP3A5—Etoposide—sarcoma	0.0247	0.0307	CbGbCtD
Mifepristone—ABCB1—Vincristine—sarcoma	0.0176	0.0218	CbGbCtD
Mifepristone—ABCB1—Etoposide—sarcoma	0.0161	0.02	CbGbCtD
Mifepristone—CYP3A4—Mitoxantrone—sarcoma	0.0153	0.019	CbGbCtD
Mifepristone—ABCB1—Doxorubicin—sarcoma	0.011	0.0136	CbGbCtD
Mifepristone—CYP3A4—Vincristine—sarcoma	0.0105	0.0131	CbGbCtD
Mifepristone—CYP2D6—Doxorubicin—sarcoma	0.0104	0.0128	CbGbCtD
Mifepristone—CYP3A4—Etoposide—sarcoma	0.00965	0.012	CbGbCtD
Mifepristone—AR—scrotum—sarcoma	0.00841	0.213	CbGeAlD
Mifepristone—CYP3A4—Doxorubicin—sarcoma	0.00658	0.00817	CbGbCtD
Mifepristone—PGR—mammary gland—sarcoma	0.0015	0.0379	CbGeAlD
Mifepristone—PGR—Ovarian Infertility Genes—GJA4—sarcoma	0.00107	0.061	CbGpPWpGaD
Mifepristone—PGR—myometrium—sarcoma	0.00107	0.0269	CbGeAlD
Mifepristone—PGR—hematopoietic system—sarcoma	0.000915	0.0231	CbGeAlD
Mifepristone—PGR—connective tissue—sarcoma	0.000881	0.0223	CbGeAlD
Mifepristone—AR—myometrium—sarcoma	0.000849	0.0214	CbGeAlD
Mifepristone—ABCC1—myometrium—sarcoma	0.000806	0.0204	CbGeAlD
Mifepristone—PGR—smooth muscle tissue—sarcoma	0.000806	0.0204	CbGeAlD
Mifepristone—CYP3A7—liver—sarcoma	0.000783	0.0198	CbGeAlD
Mifepristone—AR—seminal vesicle—sarcoma	0.000767	0.0194	CbGeAlD
Mifepristone—AR—hematopoietic system—sarcoma	0.000729	0.0184	CbGeAlD
Mifepristone—ABCC1—seminal vesicle—sarcoma	0.000728	0.0184	CbGeAlD
Mifepristone—AR—connective tissue—sarcoma	0.000702	0.0177	CbGeAlD
Mifepristone—PGR—uterus—sarcoma	0.000691	0.0175	CbGeAlD
Mifepristone—CYP3A7-CYP3A51P—liver—sarcoma	0.000666	0.0168	CbGeAlD
Mifepristone—PGR—lymphoid tissue—sarcoma	0.000644	0.0163	CbGeAlD
Mifepristone—AR—smooth muscle tissue—sarcoma	0.000642	0.0162	CbGeAlD
Mifepristone—AR—skin of body—sarcoma	0.000634	0.016	CbGeAlD
Mifepristone—NR3C1—myometrium—sarcoma	0.000615	0.0155	CbGeAlD
Mifepristone—NR3C1—embryo—sarcoma	0.000591	0.0149	CbGeAlD
Mifepristone—NR3C1—seminal vesicle—sarcoma	0.000555	0.014	CbGeAlD
Mifepristone—AR—cardiac atrium—sarcoma	0.000553	0.014	CbGeAlD
Mifepristone—AR—uterus—sarcoma	0.000551	0.0139	CbGeAlD
Mifepristone—AR—FOXA1 transcription factor network—COL18A1—sarcoma	0.000548	0.0311	CbGpPWpGaD
Mifepristone—ABCC1—S1P1 pathway—PLCG1—sarcoma	0.000547	0.031	CbGpPWpGaD
Mifepristone—PGR—Validated nuclear estrogen receptor alpha network—COL18A1—sarcoma	0.000533	0.0302	CbGpPWpGaD
Mifepristone—CYP3A5—hematopoietic system—sarcoma	0.000532	0.0134	CbGeAlD
Mifepristone—NR3C1—hematopoietic system—sarcoma	0.000528	0.0133	CbGeAlD
Mifepristone—ABCC1—cardiac atrium—sarcoma	0.000526	0.0133	CbGeAlD
Mifepristone—ABCC1—uterus—sarcoma	0.000523	0.0132	CbGeAlD
Mifepristone—AR—lymphoid tissue—sarcoma	0.000513	0.013	CbGeAlD
Mifepristone—NR3C1—connective tissue—sarcoma	0.000508	0.0128	CbGeAlD
Mifepristone—PGR—testis—sarcoma	0.000501	0.0127	CbGeAlD
Mifepristone—AR—tendon—sarcoma	0.000482	0.0122	CbGeAlD
Mifepristone—AR—Notch-mediated HES/HEY network—TLE1—sarcoma	0.000467	0.0265	CbGpPWpGaD
Mifepristone—NR3C1—smooth muscle tissue—sarcoma	0.000465	0.0117	CbGeAlD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—sarcoma	0.000463	0.0262	CbGpPWpGaD
Mifepristone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—sarcoma	0.00046	0.0261	CbGpPWpGaD
Mifepristone—NR3C1—skin of body—sarcoma	0.000459	0.0116	CbGeAlD
Mifepristone—ABCC1—tendon—sarcoma	0.000458	0.0116	CbGeAlD
Mifepristone—AR—Notch-mediated HES/HEY network—MYOD1—sarcoma	0.000437	0.0248	CbGpPWpGaD
Mifepristone—AR—Nongenotropic Androgen signaling—PLCG1—sarcoma	0.000432	0.0245	CbGpPWpGaD
Mifepristone—NR3C1—cardiac atrium—sarcoma	0.000401	0.0101	CbGeAlD
Mifepristone—Mediastinal disorder—Etoposide—sarcoma	0.0004	0.00291	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Thiotepa—sarcoma	0.0004	0.00291	CcSEcCtD
Mifepristone—AR—testis—sarcoma	0.000399	0.0101	CbGeAlD
Mifepristone—CYP3A4—hematopoietic system—sarcoma	0.000399	0.0101	CbGeAlD
Mifepristone—NR3C1—uterus—sarcoma	0.000399	0.0101	CbGeAlD
Mifepristone—Chills—Etoposide—sarcoma	0.000398	0.0029	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000397	0.00289	CcSEcCtD
Mifepristone—Myalgia—Mitoxantrone—sarcoma	0.000395	0.00288	CcSEcCtD
Mifepristone—Arthralgia—Mitoxantrone—sarcoma	0.000395	0.00288	CcSEcCtD
Mifepristone—Anxiety—Mitoxantrone—sarcoma	0.000394	0.00287	CcSEcCtD
Mifepristone—CYP2D6—hematopoietic system—sarcoma	0.000393	0.00993	CbGeAlD
Mifepristone—Discomfort—Mitoxantrone—sarcoma	0.00039	0.00285	CcSEcCtD
Mifepristone—Somnolence—Thiotepa—sarcoma	0.00039	0.00284	CcSEcCtD
Mifepristone—Oedema—Vincristine—sarcoma	0.000389	0.00284	CcSEcCtD
Mifepristone—ABCC1—S1P1 pathway—PDGFRB—sarcoma	0.000388	0.022	CbGpPWpGaD
Mifepristone—Infection—Vincristine—sarcoma	0.000386	0.00282	CcSEcCtD
Mifepristone—Hot flush—Epirubicin—sarcoma	0.000384	0.0028	CcSEcCtD
Mifepristone—Nervous system disorder—Vincristine—sarcoma	0.000381	0.00278	CcSEcCtD
Mifepristone—Decreased appetite—Thiotepa—sarcoma	0.000381	0.00278	CcSEcCtD
Mifepristone—Menopausal symptoms—Epirubicin—sarcoma	0.000381	0.00278	CcSEcCtD
Mifepristone—Dermatitis exfoliative—Epirubicin—sarcoma	0.000381	0.00278	CcSEcCtD
Mifepristone—ABCC1—testis—sarcoma	0.000379	0.00959	CbGeAlD
Mifepristone—Oedema—Mitoxantrone—sarcoma	0.000379	0.00276	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Thiotepa—sarcoma	0.000379	0.00276	CcSEcCtD
Mifepristone—Decreased appetite—Dactinomycin—sarcoma	0.000378	0.00276	CcSEcCtD
Mifepristone—Fatigue—Thiotepa—sarcoma	0.000378	0.00276	CcSEcCtD
Mifepristone—AR—liver—sarcoma	0.000378	0.00954	CbGeAlD
Mifepristone—Infection—Mitoxantrone—sarcoma	0.000376	0.00274	CcSEcCtD
Mifepristone—Fatigue—Dactinomycin—sarcoma	0.000375	0.00274	CcSEcCtD
Mifepristone—Pain—Thiotepa—sarcoma	0.000375	0.00273	CcSEcCtD
Mifepristone—Constipation—Thiotepa—sarcoma	0.000375	0.00273	CcSEcCtD
Mifepristone—Back pain—Etoposide—sarcoma	0.000373	0.00272	CcSEcCtD
Mifepristone—Pain—Dactinomycin—sarcoma	0.000372	0.00271	CcSEcCtD
Mifepristone—NR3C1—lymphoid tissue—sarcoma	0.000372	0.00939	CbGeAlD
Mifepristone—Muscle spasms—Etoposide—sarcoma	0.000371	0.00271	CcSEcCtD
Mifepristone—Anorexia—Vincristine—sarcoma	0.000371	0.0027	CcSEcCtD
Mifepristone—Hypoglycaemia—Epirubicin—sarcoma	0.000368	0.00268	CcSEcCtD
Mifepristone—Skin disorder—Mitoxantrone—sarcoma	0.000368	0.00268	CcSEcCtD
Mifepristone—PGR—lymph node—sarcoma	0.000363	0.00918	CbGeAlD
Mifepristone—Hypotension—Vincristine—sarcoma	0.000363	0.00265	CcSEcCtD
Mifepristone—Feeling abnormal—Thiotepa—sarcoma	0.000361	0.00264	CcSEcCtD
Mifepristone—Anorexia—Mitoxantrone—sarcoma	0.000361	0.00263	CcSEcCtD
Mifepristone—Pain in extremity—Epirubicin—sarcoma	0.000359	0.00262	CcSEcCtD
Mifepristone—Feeling abnormal—Dactinomycin—sarcoma	0.000359	0.00262	CcSEcCtD
Mifepristone—ABCC1—liver—sarcoma	0.000359	0.00906	CbGeAlD
Mifepristone—Gastrointestinal pain—Thiotepa—sarcoma	0.000359	0.00262	CcSEcCtD
Mifepristone—Ill-defined disorder—Etoposide—sarcoma	0.000358	0.00261	CcSEcCtD
Mifepristone—Gastrointestinal pain—Dactinomycin—sarcoma	0.000356	0.0026	CcSEcCtD
Mifepristone—Hot flush—Doxorubicin—sarcoma	0.000355	0.00259	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Vincristine—sarcoma	0.000354	0.00258	CcSEcCtD
Mifepristone—Hypotension—Mitoxantrone—sarcoma	0.000354	0.00258	CcSEcCtD
Mifepristone—Dermatitis exfoliative—Doxorubicin—sarcoma	0.000352	0.00257	CcSEcCtD
Mifepristone—Menopausal symptoms—Doxorubicin—sarcoma	0.000352	0.00257	CcSEcCtD
Mifepristone—Insomnia—Vincristine—sarcoma	0.000352	0.00256	CcSEcCtD
Mifepristone—NR3C1—tendon—sarcoma	0.000349	0.00883	CbGeAlD
Mifepristone—Urticaria—Thiotepa—sarcoma	0.000348	0.00254	CcSEcCtD
Mifepristone—Malaise—Etoposide—sarcoma	0.000348	0.00254	CcSEcCtD
Mifepristone—Body temperature increased—Thiotepa—sarcoma	0.000347	0.00253	CcSEcCtD
Mifepristone—Abdominal pain—Thiotepa—sarcoma	0.000347	0.00253	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000345	0.00252	CcSEcCtD
Mifepristone—Abdominal pain—Dactinomycin—sarcoma	0.000344	0.00251	CcSEcCtD
Mifepristone—Body temperature increased—Dactinomycin—sarcoma	0.000344	0.00251	CcSEcCtD
Mifepristone—Hypoglycaemia—Doxorubicin—sarcoma	0.000341	0.00248	CcSEcCtD
Mifepristone—NR3C1—bone marrow—sarcoma	0.000338	0.00855	CbGeAlD
Mifepristone—Decreased appetite—Vincristine—sarcoma	0.000338	0.00247	CcSEcCtD
Mifepristone—Dyspnoea—Mitoxantrone—sarcoma	0.000338	0.00246	CcSEcCtD
Mifepristone—Somnolence—Mitoxantrone—sarcoma	0.000337	0.00246	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Vincristine—sarcoma	0.000336	0.00245	CcSEcCtD
Mifepristone—Fatigue—Vincristine—sarcoma	0.000335	0.00244	CcSEcCtD
Mifepristone—Hypertension—Etoposide—sarcoma	0.000333	0.00243	CcSEcCtD
Mifepristone—Pain—Vincristine—sarcoma	0.000333	0.00243	CcSEcCtD
Mifepristone—Constipation—Vincristine—sarcoma	0.000333	0.00243	CcSEcCtD
Mifepristone—Pain in extremity—Doxorubicin—sarcoma	0.000332	0.00242	CcSEcCtD
Mifepristone—Decreased appetite—Mitoxantrone—sarcoma	0.000329	0.0024	CcSEcCtD
Mifepristone—ABCB1—myometrium—sarcoma	0.000329	0.00832	CbGeAlD
Mifepristone—Hypokalaemia—Epirubicin—sarcoma	0.000327	0.00238	CcSEcCtD
Mifepristone—Fatigue—Mitoxantrone—sarcoma	0.000327	0.00238	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000326	0.00238	CcSEcCtD
Mifepristone—Discomfort—Etoposide—sarcoma	0.000325	0.00237	CcSEcCtD
Mifepristone—Breast disorder—Epirubicin—sarcoma	0.000325	0.00237	CcSEcCtD
Mifepristone—Pain—Mitoxantrone—sarcoma	0.000324	0.00236	CcSEcCtD
Mifepristone—Constipation—Mitoxantrone—sarcoma	0.000324	0.00236	CcSEcCtD
Mifepristone—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000324	0.00236	CcSEcCtD
Mifepristone—Hypersensitivity—Thiotepa—sarcoma	0.000323	0.00236	CcSEcCtD
Mifepristone—Nasopharyngitis—Epirubicin—sarcoma	0.000321	0.00234	CcSEcCtD
Mifepristone—ABCC1—S1P1 pathway—KDR—sarcoma	0.000321	0.0182	CbGpPWpGaD
Mifepristone—Hypersensitivity—Dactinomycin—sarcoma	0.000321	0.00234	CcSEcCtD
Mifepristone—Gastrointestinal pain—Vincristine—sarcoma	0.000318	0.00232	CcSEcCtD
Mifepristone—Muscular weakness—Epirubicin—sarcoma	0.000317	0.00231	CcSEcCtD
Mifepristone—ABCB1—embryo—sarcoma	0.000317	0.008	CbGeAlD
Mifepristone—Asthenia—Thiotepa—sarcoma	0.000315	0.00229	CcSEcCtD
Mifepristone—Infection—Etoposide—sarcoma	0.000313	0.00228	CcSEcCtD
Mifepristone—Asthenia—Dactinomycin—sarcoma	0.000312	0.00228	CcSEcCtD
Mifepristone—Feeling abnormal—Mitoxantrone—sarcoma	0.000312	0.00228	CcSEcCtD
Mifepristone—Pruritus—Thiotepa—sarcoma	0.00031	0.00226	CcSEcCtD
Mifepristone—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00031	0.00226	CcSEcCtD
Mifepristone—Abdominal pain—Vincristine—sarcoma	0.000307	0.00224	CcSEcCtD
Mifepristone—Body temperature increased—Vincristine—sarcoma	0.000307	0.00224	CcSEcCtD
Mifepristone—Skin disorder—Etoposide—sarcoma	0.000306	0.00223	CcSEcCtD
Mifepristone—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—sarcoma	0.000306	0.0173	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TLE1—sarcoma	0.000305	0.0173	CbGpPWpGaD
Mifepristone—Hypokalaemia—Doxorubicin—sarcoma	0.000303	0.00221	CcSEcCtD
Mifepristone—Urticaria—Mitoxantrone—sarcoma	0.000301	0.00219	CcSEcCtD
Mifepristone—Breast disorder—Doxorubicin—sarcoma	0.0003	0.00219	CcSEcCtD
Mifepristone—Anorexia—Etoposide—sarcoma	0.0003	0.00219	CcSEcCtD
Mifepristone—Diarrhoea—Thiotepa—sarcoma	0.0003	0.00219	CcSEcCtD
Mifepristone—Body temperature increased—Mitoxantrone—sarcoma	0.000299	0.00218	CcSEcCtD
Mifepristone—Abdominal pain—Mitoxantrone—sarcoma	0.000299	0.00218	CcSEcCtD
Mifepristone—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000299	0.00218	CcSEcCtD
Mifepristone—Diarrhoea—Dactinomycin—sarcoma	0.000298	0.00217	CcSEcCtD
Mifepristone—ABCB1—seminal vesicle—sarcoma	0.000297	0.00751	CbGeAlD
Mifepristone—Nasopharyngitis—Doxorubicin—sarcoma	0.000297	0.00217	CcSEcCtD
Mifepristone—Hypotension—Etoposide—sarcoma	0.000294	0.00215	CcSEcCtD
Mifepristone—Muscular weakness—Doxorubicin—sarcoma	0.000293	0.00214	CcSEcCtD
Mifepristone—Dizziness—Thiotepa—sarcoma	0.00029	0.00211	CcSEcCtD
Mifepristone—AR—lymph node—sarcoma	0.00029	0.00732	CbGeAlD
Mifepristone—NR3C1—testis—sarcoma	0.000289	0.00731	CbGeAlD
Mifepristone—Hypersensitivity—Vincristine—sarcoma	0.000287	0.00209	CcSEcCtD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.000283	0.0161	CbGpPWpGaD
Mifepristone—ABCB1—hematopoietic system—sarcoma	0.000283	0.00714	CbGeAlD
Mifepristone—Dyspnoea—Etoposide—sarcoma	0.000281	0.00205	CcSEcCtD
Mifepristone—Somnolence—Etoposide—sarcoma	0.00028	0.00204	CcSEcCtD
Mifepristone—Hypersensitivity—Mitoxantrone—sarcoma	0.000279	0.00203	CcSEcCtD
Mifepristone—Asthenia—Vincristine—sarcoma	0.000279	0.00203	CcSEcCtD
Mifepristone—Vomiting—Thiotepa—sarcoma	0.000279	0.00203	CcSEcCtD
Mifepristone—Infestation NOS—Epirubicin—sarcoma	0.000277	0.00202	CcSEcCtD
Mifepristone—Infestation—Epirubicin—sarcoma	0.000277	0.00202	CcSEcCtD
Mifepristone—Vomiting—Dactinomycin—sarcoma	0.000277	0.00202	CcSEcCtD
Mifepristone—Rash—Thiotepa—sarcoma	0.000277	0.00202	CcSEcCtD
Mifepristone—Dermatitis—Thiotepa—sarcoma	0.000276	0.00201	CcSEcCtD
Mifepristone—CYP3A5—liver—sarcoma	0.000276	0.00696	CbGeAlD
Mifepristone—ABCC1—lymph node—sarcoma	0.000275	0.00695	CbGeAlD
Mifepristone—Headache—Thiotepa—sarcoma	0.000275	0.002	CcSEcCtD
Mifepristone—Rash—Dactinomycin—sarcoma	0.000274	0.002	CcSEcCtD
Mifepristone—Decreased appetite—Etoposide—sarcoma	0.000274	0.002	CcSEcCtD
Mifepristone—NR3C1—liver—sarcoma	0.000274	0.00691	CbGeAlD
Mifepristone—Gastrointestinal disorder—Etoposide—sarcoma	0.000272	0.00198	CcSEcCtD
Mifepristone—Asthenia—Mitoxantrone—sarcoma	0.000272	0.00198	CcSEcCtD
Mifepristone—Fatigue—Etoposide—sarcoma	0.000272	0.00198	CcSEcCtD
Mifepristone—Constipation—Etoposide—sarcoma	0.000269	0.00196	CcSEcCtD
Mifepristone—Pain—Etoposide—sarcoma	0.000269	0.00196	CcSEcCtD
Mifepristone—Diarrhoea—Vincristine—sarcoma	0.000266	0.00194	CcSEcCtD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—sarcoma	0.000266	0.0151	CbGpPWpGaD
Mifepristone—Nausea—Thiotepa—sarcoma	0.00026	0.0019	CcSEcCtD
Mifepristone—Sinusitis—Epirubicin—sarcoma	0.00026	0.00189	CcSEcCtD
Mifepristone—Feeling abnormal—Etoposide—sarcoma	0.00026	0.00189	CcSEcCtD
Mifepristone—Diarrhoea—Mitoxantrone—sarcoma	0.000259	0.00189	CcSEcCtD
Mifepristone—Nausea—Dactinomycin—sarcoma	0.000259	0.00189	CcSEcCtD
Mifepristone—Gastrointestinal pain—Etoposide—sarcoma	0.000258	0.00188	CcSEcCtD
Mifepristone—Dizziness—Vincristine—sarcoma	0.000257	0.00188	CcSEcCtD
Mifepristone—Infestation NOS—Doxorubicin—sarcoma	0.000256	0.00187	CcSEcCtD
Mifepristone—Infestation—Doxorubicin—sarcoma	0.000256	0.00187	CcSEcCtD
Mifepristone—Urticaria—Etoposide—sarcoma	0.00025	0.00182	CcSEcCtD
Mifepristone—Haemoglobin—Epirubicin—sarcoma	0.00025	0.00182	CcSEcCtD
Mifepristone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—CREB1—sarcoma	0.000249	0.0141	CbGpPWpGaD
Mifepristone—Body temperature increased—Etoposide—sarcoma	0.000249	0.00182	CcSEcCtD
Mifepristone—Abdominal pain—Etoposide—sarcoma	0.000249	0.00182	CcSEcCtD
Mifepristone—Haemorrhage—Epirubicin—sarcoma	0.000249	0.00181	CcSEcCtD
Mifepristone—Vomiting—Vincristine—sarcoma	0.000247	0.0018	CcSEcCtD
Mifepristone—Rash—Vincristine—sarcoma	0.000245	0.00179	CcSEcCtD
Mifepristone—Dermatitis—Vincristine—sarcoma	0.000245	0.00179	CcSEcCtD
Mifepristone—Oedema peripheral—Epirubicin—sarcoma	0.000245	0.00179	CcSEcCtD
Mifepristone—Connective tissue disorder—Epirubicin—sarcoma	0.000244	0.00178	CcSEcCtD
Mifepristone—Headache—Vincristine—sarcoma	0.000244	0.00178	CcSEcCtD
Mifepristone—Vomiting—Mitoxantrone—sarcoma	0.000241	0.00176	CcSEcCtD
Mifepristone—Sinusitis—Doxorubicin—sarcoma	0.00024	0.00175	CcSEcCtD
Mifepristone—Rash—Mitoxantrone—sarcoma	0.000239	0.00174	CcSEcCtD
Mifepristone—Dermatitis—Mitoxantrone—sarcoma	0.000239	0.00174	CcSEcCtD
Mifepristone—Headache—Mitoxantrone—sarcoma	0.000237	0.00173	CcSEcCtD
Mifepristone—Hypersensitivity—Etoposide—sarcoma	0.000232	0.00169	CcSEcCtD
Mifepristone—Haemoglobin—Doxorubicin—sarcoma	0.000231	0.00169	CcSEcCtD
Mifepristone—Nausea—Vincristine—sarcoma	0.000231	0.00168	CcSEcCtD
Mifepristone—Haemorrhage—Doxorubicin—sarcoma	0.00023	0.00168	CcSEcCtD
Mifepristone—Oedema peripheral—Doxorubicin—sarcoma	0.000227	0.00165	CcSEcCtD
Mifepristone—Asthenia—Etoposide—sarcoma	0.000226	0.00165	CcSEcCtD
Mifepristone—Connective tissue disorder—Doxorubicin—sarcoma	0.000226	0.00165	CcSEcCtD
Mifepristone—Angiopathy—Epirubicin—sarcoma	0.000226	0.00164	CcSEcCtD
Mifepristone—Nausea—Mitoxantrone—sarcoma	0.000225	0.00164	CcSEcCtD
Mifepristone—Mediastinal disorder—Epirubicin—sarcoma	0.000224	0.00163	CcSEcCtD
Mifepristone—Chills—Epirubicin—sarcoma	0.000223	0.00163	CcSEcCtD
Mifepristone—Pruritus—Etoposide—sarcoma	0.000223	0.00163	CcSEcCtD
Mifepristone—AR—Nongenotropic Androgen signaling—CREB1—sarcoma	0.000222	0.0126	CbGpPWpGaD
Mifepristone—NR3C1—Transcription factor regulation in adipogenesis—CREB1—sarcoma	0.000222	0.0126	CbGpPWpGaD
Mifepristone—Mental disorder—Epirubicin—sarcoma	0.000218	0.00159	CcSEcCtD
Mifepristone—Malnutrition—Epirubicin—sarcoma	0.000216	0.00158	CcSEcCtD
Mifepristone—Diarrhoea—Etoposide—sarcoma	0.000216	0.00157	CcSEcCtD
Mifepristone—CYP2D6—testis—sarcoma	0.000215	0.00544	CbGeAlD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.000215	0.0122	CbGpPWpGaD
Mifepristone—ABCB1—uterus—sarcoma	0.000213	0.00539	CbGeAlD
Mifepristone—NR3C1—lymph node—sarcoma	0.00021	0.0053	CbGeAlD
Mifepristone—Back pain—Epirubicin—sarcoma	0.000209	0.00153	CcSEcCtD
Mifepristone—Angiopathy—Doxorubicin—sarcoma	0.000209	0.00152	CcSEcCtD
Mifepristone—Dizziness—Etoposide—sarcoma	0.000208	0.00152	CcSEcCtD
Mifepristone—Muscle spasms—Epirubicin—sarcoma	0.000208	0.00152	CcSEcCtD
Mifepristone—Mediastinal disorder—Doxorubicin—sarcoma	0.000207	0.00151	CcSEcCtD
Mifepristone—CYP3A4—liver—sarcoma	0.000207	0.00523	CbGeAlD
Mifepristone—Chills—Doxorubicin—sarcoma	0.000206	0.0015	CcSEcCtD
Mifepristone—CYP2D6—liver—sarcoma	0.000204	0.00514	CbGeAlD
Mifepristone—Mental disorder—Doxorubicin—sarcoma	0.000201	0.00147	CcSEcCtD
Mifepristone—Ill-defined disorder—Epirubicin—sarcoma	0.000201	0.00146	CcSEcCtD
Mifepristone—Vomiting—Etoposide—sarcoma	0.0002	0.00146	CcSEcCtD
Mifepristone—Malnutrition—Doxorubicin—sarcoma	0.0002	0.00146	CcSEcCtD
Mifepristone—AR—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.000199	0.0113	CbGpPWpGaD
Mifepristone—ABCB1—lymphoid tissue—sarcoma	0.000199	0.00503	CbGeAlD
Mifepristone—Rash—Etoposide—sarcoma	0.000199	0.00145	CcSEcCtD
Mifepristone—Dermatitis—Etoposide—sarcoma	0.000198	0.00145	CcSEcCtD
Mifepristone—Headache—Etoposide—sarcoma	0.000197	0.00144	CcSEcCtD
Mifepristone—Malaise—Epirubicin—sarcoma	0.000195	0.00142	CcSEcCtD
Mifepristone—Back pain—Doxorubicin—sarcoma	0.000194	0.00141	CcSEcCtD
Mifepristone—Muscle spasms—Doxorubicin—sarcoma	0.000192	0.0014	CcSEcCtD
Mifepristone—Nausea—Etoposide—sarcoma	0.000187	0.00136	CcSEcCtD
Mifepristone—Hypertension—Epirubicin—sarcoma	0.000187	0.00136	CcSEcCtD
Mifepristone—Ill-defined disorder—Doxorubicin—sarcoma	0.000186	0.00135	CcSEcCtD
Mifepristone—Myalgia—Epirubicin—sarcoma	0.000184	0.00134	CcSEcCtD
Mifepristone—Arthralgia—Epirubicin—sarcoma	0.000184	0.00134	CcSEcCtD
Mifepristone—Anxiety—Epirubicin—sarcoma	0.000184	0.00134	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000183	0.00133	CcSEcCtD
Mifepristone—Discomfort—Epirubicin—sarcoma	0.000182	0.00133	CcSEcCtD
Mifepristone—AR—Notch-mediated HES/HEY network—KDR—sarcoma	0.000182	0.0103	CbGpPWpGaD
Mifepristone—ABCB1—bone marrow—sarcoma	0.000181	0.00458	CbGeAlD
Mifepristone—Malaise—Doxorubicin—sarcoma	0.000181	0.00132	CcSEcCtD
Mifepristone—Dry mouth—Epirubicin—sarcoma	0.00018	0.00131	CcSEcCtD
Mifepristone—ABCC1—S1P1 pathway—VEGFA—sarcoma	0.000177	0.01	CbGpPWpGaD
Mifepristone—Oedema—Epirubicin—sarcoma	0.000177	0.00129	CcSEcCtD
Mifepristone—Infection—Epirubicin—sarcoma	0.000175	0.00128	CcSEcCtD
Mifepristone—Nervous system disorder—Epirubicin—sarcoma	0.000173	0.00126	CcSEcCtD
Mifepristone—Hypertension—Doxorubicin—sarcoma	0.000173	0.00126	CcSEcCtD
Mifepristone—Skin disorder—Epirubicin—sarcoma	0.000172	0.00125	CcSEcCtD
Mifepristone—Arthralgia—Doxorubicin—sarcoma	0.00017	0.00124	CcSEcCtD
Mifepristone—Myalgia—Doxorubicin—sarcoma	0.00017	0.00124	CcSEcCtD
Mifepristone—Anxiety—Doxorubicin—sarcoma	0.00017	0.00124	CcSEcCtD
Mifepristone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000169	0.00123	CcSEcCtD
Mifepristone—Discomfort—Doxorubicin—sarcoma	0.000168	0.00123	CcSEcCtD
Mifepristone—Anorexia—Epirubicin—sarcoma	0.000168	0.00123	CcSEcCtD
Mifepristone—Dry mouth—Doxorubicin—sarcoma	0.000167	0.00122	CcSEcCtD
Mifepristone—Hypotension—Epirubicin—sarcoma	0.000165	0.0012	CcSEcCtD
Mifepristone—Oedema—Doxorubicin—sarcoma	0.000163	0.00119	CcSEcCtD
Mifepristone—Infection—Doxorubicin—sarcoma	0.000162	0.00118	CcSEcCtD
Mifepristone—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000161	0.00915	CbGpPWpGaD
Mifepristone—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000161	0.00117	CcSEcCtD
Mifepristone—Nervous system disorder—Doxorubicin—sarcoma	0.00016	0.00117	CcSEcCtD
Mifepristone—Insomnia—Epirubicin—sarcoma	0.00016	0.00116	CcSEcCtD
Mifepristone—Skin disorder—Doxorubicin—sarcoma	0.000159	0.00116	CcSEcCtD
Mifepristone—Dyspnoea—Epirubicin—sarcoma	0.000157	0.00115	CcSEcCtD
Mifepristone—Somnolence—Epirubicin—sarcoma	0.000157	0.00114	CcSEcCtD
Mifepristone—Anorexia—Doxorubicin—sarcoma	0.000156	0.00114	CcSEcCtD
Mifepristone—ABCB1—testis—sarcoma	0.000155	0.00391	CbGeAlD
Mifepristone—Decreased appetite—Epirubicin—sarcoma	0.000154	0.00112	CcSEcCtD
Mifepristone—Hypotension—Doxorubicin—sarcoma	0.000153	0.00111	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Epirubicin—sarcoma	0.000152	0.00111	CcSEcCtD
Mifepristone—Fatigue—Epirubicin—sarcoma	0.000152	0.00111	CcSEcCtD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.000151	0.00858	CbGpPWpGaD
Mifepristone—Pain—Epirubicin—sarcoma	0.000151	0.0011	CcSEcCtD
Mifepristone—Constipation—Epirubicin—sarcoma	0.000151	0.0011	CcSEcCtD
Mifepristone—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000149	0.00109	CcSEcCtD
Mifepristone—Insomnia—Doxorubicin—sarcoma	0.000148	0.00108	CcSEcCtD
Mifepristone—ABCB1—liver—sarcoma	0.000146	0.0037	CbGeAlD
Mifepristone—Dyspnoea—Doxorubicin—sarcoma	0.000146	0.00106	CcSEcCtD
Mifepristone—Feeling abnormal—Epirubicin—sarcoma	0.000146	0.00106	CcSEcCtD
Mifepristone—Somnolence—Doxorubicin—sarcoma	0.000145	0.00106	CcSEcCtD
Mifepristone—Gastrointestinal pain—Epirubicin—sarcoma	0.000144	0.00105	CcSEcCtD
Mifepristone—AR—Nongenotropic Androgen signaling—SRC—sarcoma	0.000143	0.00813	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.000142	0.00806	CbGpPWpGaD
Mifepristone—Decreased appetite—Doxorubicin—sarcoma	0.000142	0.00104	CcSEcCtD
Mifepristone—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000141	0.00103	CcSEcCtD
Mifepristone—Fatigue—Doxorubicin—sarcoma	0.000141	0.00103	CcSEcCtD
Mifepristone—Urticaria—Epirubicin—sarcoma	0.00014	0.00102	CcSEcCtD
Mifepristone—Pain—Doxorubicin—sarcoma	0.00014	0.00102	CcSEcCtD
Mifepristone—Constipation—Doxorubicin—sarcoma	0.00014	0.00102	CcSEcCtD
Mifepristone—Body temperature increased—Epirubicin—sarcoma	0.00014	0.00102	CcSEcCtD
Mifepristone—Abdominal pain—Epirubicin—sarcoma	0.00014	0.00102	CcSEcCtD
Mifepristone—Feeling abnormal—Doxorubicin—sarcoma	0.000135	0.000982	CcSEcCtD
Mifepristone—Gastrointestinal pain—Doxorubicin—sarcoma	0.000134	0.000974	CcSEcCtD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000132	0.00751	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—FOXO1—sarcoma	0.000132	0.00747	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000131	0.00742	CbGpPWpGaD
Mifepristone—Hypersensitivity—Epirubicin—sarcoma	0.00013	0.000949	CcSEcCtD
Mifepristone—Urticaria—Doxorubicin—sarcoma	0.00013	0.000947	CcSEcCtD
Mifepristone—Body temperature increased—Doxorubicin—sarcoma	0.000129	0.000942	CcSEcCtD
Mifepristone—Abdominal pain—Doxorubicin—sarcoma	0.000129	0.000942	CcSEcCtD
Mifepristone—NR3C1—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	0.000127	0.00723	CbGpPWpGaD
Mifepristone—Asthenia—Epirubicin—sarcoma	0.000127	0.000924	CcSEcCtD
Mifepristone—Pruritus—Epirubicin—sarcoma	0.000125	0.000911	CcSEcCtD
Mifepristone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000124	0.00704	CbGpPWpGaD
Mifepristone—CYP2D6—Melatonin metabolism and effects—FOXO1—sarcoma	0.000124	0.00704	CbGpPWpGaD
Mifepristone—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000122	0.00691	CbGpPWpGaD
Mifepristone—Diarrhoea—Epirubicin—sarcoma	0.000121	0.000881	CcSEcCtD
Mifepristone—AR—FOXA1 transcription factor network—JUN—sarcoma	0.000121	0.00685	CbGpPWpGaD
Mifepristone—Hypersensitivity—Doxorubicin—sarcoma	0.00012	0.000878	CcSEcCtD
Mifepristone—AR—Regulation of Androgen receptor activity—MDM2—sarcoma	0.00012	0.00679	CbGpPWpGaD
Mifepristone—PGR—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	0.000118	0.00668	CbGpPWpGaD
Mifepristone—PGR—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	0.000117	0.00666	CbGpPWpGaD
Mifepristone—Asthenia—Doxorubicin—sarcoma	0.000117	0.000855	CcSEcCtD
Mifepristone—Dizziness—Epirubicin—sarcoma	0.000117	0.000852	CcSEcCtD
Mifepristone—Pruritus—Doxorubicin—sarcoma	0.000116	0.000843	CcSEcCtD
Mifepristone—AR—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000116	0.00656	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—FOXO1—sarcoma	0.000113	0.00639	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—PDGFRB—sarcoma	0.000113	0.00638	CbGpPWpGaD
Mifepristone—Vomiting—Epirubicin—sarcoma	0.000112	0.000819	CcSEcCtD
Mifepristone—ABCB1—lymph node—sarcoma	0.000112	0.00284	CbGeAlD
Mifepristone—Diarrhoea—Doxorubicin—sarcoma	0.000112	0.000815	CcSEcCtD
Mifepristone—Rash—Epirubicin—sarcoma	0.000111	0.000812	CcSEcCtD
Mifepristone—Dermatitis—Epirubicin—sarcoma	0.000111	0.000811	CcSEcCtD
Mifepristone—PGR—Signaling by ERBB4—PDGFRA—sarcoma	0.000111	0.00628	CbGpPWpGaD
Mifepristone—Headache—Epirubicin—sarcoma	0.000111	0.000807	CcSEcCtD
Mifepristone—Dizziness—Doxorubicin—sarcoma	0.000108	0.000788	CcSEcCtD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.000108	0.00611	CbGpPWpGaD
Mifepristone—NR3C1—Circadian Clock—CREB1—sarcoma	0.000107	0.00604	CbGpPWpGaD
Mifepristone—Nausea—Epirubicin—sarcoma	0.000105	0.000765	CcSEcCtD
Mifepristone—AR—Regulation of Androgen receptor activity—JUN—sarcoma	0.000104	0.0059	CbGpPWpGaD
Mifepristone—Vomiting—Doxorubicin—sarcoma	0.000104	0.000758	CcSEcCtD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.000103	0.00585	CbGpPWpGaD
Mifepristone—Rash—Doxorubicin—sarcoma	0.000103	0.000751	CcSEcCtD
Mifepristone—Dermatitis—Doxorubicin—sarcoma	0.000103	0.000751	CcSEcCtD
Mifepristone—Headache—Doxorubicin—sarcoma	0.000102	0.000746	CcSEcCtD
Mifepristone—AR—Nongenotropic Androgen signaling—HRAS—sarcoma	0.000101	0.00572	CbGpPWpGaD
Mifepristone—Nausea—Doxorubicin—sarcoma	9.71e-05	0.000708	CcSEcCtD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	9.69e-05	0.0055	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—CREB1—sarcoma	9.56e-05	0.00542	CbGpPWpGaD
Mifepristone—PGR—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	9.44e-05	0.00535	CbGpPWpGaD
Mifepristone—AR—Regulation of Androgen receptor activity—SRC—sarcoma	9.33e-05	0.00529	CbGpPWpGaD
Mifepristone—AR—Coregulation of Androgen receptor activity—CCND1—sarcoma	9.32e-05	0.00529	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	9.24e-05	0.00524	CbGpPWpGaD
Mifepristone—AR—Coregulation of Androgen receptor activity—CTNNB1—sarcoma	9.23e-05	0.00523	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—MDM2—sarcoma	9.08e-05	0.00515	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—CREB1—sarcoma	8.79e-05	0.00498	CbGpPWpGaD
Mifepristone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	8.64e-05	0.0049	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	8.63e-05	0.0049	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—KIT—sarcoma	8.59e-05	0.00487	CbGpPWpGaD
Mifepristone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	8.51e-05	0.00483	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—CREB1—sarcoma	8.18e-05	0.00464	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—MDM2—sarcoma	7.91e-05	0.00449	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—JUN—sarcoma	7.89e-05	0.00448	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	7.82e-05	0.00443	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—CREB1—sarcoma	7.74e-05	0.00439	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	7.5e-05	0.00425	CbGpPWpGaD
Mifepristone—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.5e-05	0.00425	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	7.49e-05	0.00425	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	7.43e-05	0.00421	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	7.41e-05	0.0042	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—FOXO1—sarcoma	7.38e-05	0.00419	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—FUS—sarcoma	7.24e-05	0.00411	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of Androgen receptor activity—SRC—sarcoma	7.08e-05	0.00402	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	7.03e-05	0.00399	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—CCND1—sarcoma	6.89e-05	0.00391	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—JUN—sarcoma	6.87e-05	0.0039	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—CTNNB1—sarcoma	6.82e-05	0.00387	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—MDM2—sarcoma	6.76e-05	0.00384	CbGpPWpGaD
Mifepristone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	6.6e-05	0.00374	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—IL2—sarcoma	6.5e-05	0.00368	CbGpPWpGaD
Mifepristone—NR3C1—Endoderm Differentiation—CTNNB1—sarcoma	6.42e-05	0.00364	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—sarcoma	6.41e-05	0.00363	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—CCND1—sarcoma	6.33e-05	0.00359	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—JUN—sarcoma	6.32e-05	0.00358	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—CTNNB1—sarcoma	6.27e-05	0.00356	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—CREB1—sarcoma	6.26e-05	0.00355	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—SRC—sarcoma	6.17e-05	0.0035	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—CREB1—sarcoma	6.1e-05	0.00346	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	6.02e-05	0.00341	CbGpPWpGaD
Mifepristone—AR—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	5.96e-05	0.00338	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—PDGFRA—sarcoma	5.81e-05	0.00329	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—IL2—sarcoma	5.72e-05	0.00325	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	5.62e-05	0.00319	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—JUN—sarcoma	5.57e-05	0.00316	CbGpPWpGaD
Mifepristone—AR—Gene Expression—FUS—sarcoma	5.52e-05	0.00313	CbGpPWpGaD
Mifepristone—AR—Androgen receptor signaling pathway—EGFR—sarcoma	5.4e-05	0.00307	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	5.4e-05	0.00306	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—CREB1—sarcoma	5.35e-05	0.00304	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	5.19e-05	0.00294	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—MDM2—sarcoma	5.18e-05	0.00294	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—MYC—sarcoma	5.08e-05	0.00288	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—NRAS—sarcoma	5.07e-05	0.00288	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	4.95e-05	0.00281	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CREB1—sarcoma	4.63e-05	0.00263	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—EGFR—sarcoma	4.62e-05	0.00262	CbGpPWpGaD
Mifepristone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	4.52e-05	0.00256	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—CCND1—sarcoma	4.51e-05	0.00256	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—JUN—sarcoma	4.5e-05	0.00255	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	4.47e-05	0.00253	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—JUN—sarcoma	4.39e-05	0.00249	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—KRAS—sarcoma	4.37e-05	0.00248	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—CTNNB1—sarcoma	4.35e-05	0.00247	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.29e-05	0.00243	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—FUS—sarcoma	4.18e-05	0.00237	CbGpPWpGaD
Mifepristone—NR3C1—AP-1 transcription factor network—TP53—sarcoma	4.17e-05	0.00237	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	3.93e-05	0.00223	CbGpPWpGaD
Mifepristone—AR—SIDS Susceptibility Pathways—VEGFA—sarcoma	3.83e-05	0.00217	CbGpPWpGaD
Mifepristone—NR3C1—Adipogenesis—CTNNB1—sarcoma	3.82e-05	0.00217	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.74e-05	0.00212	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.73e-05	0.00212	CbGpPWpGaD
Mifepristone—PGR—Signaling by ERBB4—HRAS—sarcoma	3.71e-05	0.00211	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.7e-05	0.0021	CbGpPWpGaD
Mifepristone—NR3C1—Glucocorticoid receptor regulatory network—TP53—sarcoma	3.68e-05	0.00208	CbGpPWpGaD
Mifepristone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	3.63e-05	0.00206	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—MYC—sarcoma	3.62e-05	0.00205	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	3.56e-05	0.00202	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—EGFR—sarcoma	3.54e-05	0.00201	CbGpPWpGaD
Mifepristone—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	3.37e-05	0.00191	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.35e-05	0.0019	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—KRAS—sarcoma	3.34e-05	0.0019	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—JUN—sarcoma	3.33e-05	0.00189	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—CTNNB1—sarcoma	3.3e-05	0.00187	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.26e-05	0.00185	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—IL2—sarcoma	3.17e-05	0.0018	CbGpPWpGaD
Mifepristone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	3.11e-05	0.00176	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TLE1—sarcoma	3.1e-05	0.00176	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	3e-05	0.0017	CbGpPWpGaD
Mifepristone—AR—Integrated Breast Cancer Pathway—TP53—sarcoma	2.97e-05	0.00169	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.93e-05	0.00166	CbGpPWpGaD
Mifepristone—NR3C1—SIDS Susceptibility Pathways—VEGFA—sarcoma	2.91e-05	0.00165	CbGpPWpGaD
Mifepristone—ABCC1—Disease—TLE1—sarcoma	2.89e-05	0.00164	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	2.87e-05	0.00163	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.77e-05	0.00157	CbGpPWpGaD
Mifepristone—ABCB1—Allograft Rejection—VEGFA—sarcoma	2.69e-05	0.00153	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—VEGFC—sarcoma	2.62e-05	0.00149	CbGpPWpGaD
Mifepristone—ABCC1—Disease—NPM1—sarcoma	2.61e-05	0.00148	CbGpPWpGaD
Mifepristone—AR—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.46e-05	0.0014	CbGpPWpGaD
Mifepristone—ABCC1—Disease—ENO2—sarcoma	2.26e-05	0.00128	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	2.11e-05	0.0012	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—FLT1—sarcoma	2.09e-05	0.00119	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—PLCG1—sarcoma	2.06e-05	0.00117	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CXCR4—sarcoma	1.98e-05	0.00112	CbGpPWpGaD
Mifepristone—PGR—Generic Transcription Pathway—MYC—sarcoma	1.96e-05	0.00111	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—ATF1—sarcoma	1.95e-05	0.00111	CbGpPWpGaD
Mifepristone—ABCC1—Disease—PLCG1—sarcoma	1.92e-05	0.00109	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—ENO2—sarcoma	1.89e-05	0.00107	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—HBA1—sarcoma	1.88e-05	0.00107	CbGpPWpGaD
Mifepristone—ABCC1—Disease—CXCR4—sarcoma	1.84e-05	0.00105	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	1.75e-05	0.000992	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—ENO2—sarcoma	1.65e-05	0.000937	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—HBA1—sarcoma	1.64e-05	0.000931	CbGpPWpGaD
Mifepristone—ABCC1—Metabolism—PLCG1—sarcoma	1.61e-05	0.000911	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—IGF1R—sarcoma	1.53e-05	0.00087	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.52e-05	0.000864	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.52e-05	0.000863	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.51e-05	0.000856	CbGpPWpGaD
Mifepristone—AR—Generic Transcription Pathway—MYC—sarcoma	1.49e-05	0.000845	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—FOXO1—sarcoma	1.46e-05	0.000828	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—PDGFRB—sarcoma	1.46e-05	0.000827	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—PDGFRA—sarcoma	1.43e-05	0.000814	CbGpPWpGaD
Mifepristone—CYP3A7—Metabolism—PLCG1—sarcoma	1.4e-05	0.000795	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.36e-05	0.000774	CbGpPWpGaD
Mifepristone—ABCC1—Disease—FOXO1—sarcoma	1.36e-05	0.000772	CbGpPWpGaD
Mifepristone—ABCC1—Disease—PDGFRB—sarcoma	1.36e-05	0.000771	CbGpPWpGaD
Mifepristone—ABCC1—Disease—PDGFRA—sarcoma	1.34e-05	0.000759	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.33e-05	0.000754	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.22e-05	0.000693	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—KDR—sarcoma	1.21e-05	0.000685	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.2e-05	0.000678	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—ENO2—sarcoma	1.19e-05	0.000677	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—HBA1—sarcoma	1.19e-05	0.000673	CbGpPWpGaD
Mifepristone—NR3C1—Generic Transcription Pathway—MYC—sarcoma	1.13e-05	0.000641	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.13e-05	0.000641	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—KIT—sarcoma	1.11e-05	0.000631	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CREB1—sarcoma	1.06e-05	0.000601	CbGpPWpGaD
Mifepristone—ABCC1—Disease—KIT—sarcoma	1.04e-05	0.000588	CbGpPWpGaD
Mifepristone—CYP3A5—Metabolism—PLCG1—sarcoma	1.01e-05	0.000574	CbGpPWpGaD
Mifepristone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1e-05	0.000569	CbGpPWpGaD
Mifepristone—ABCC1—Disease—CREB1—sarcoma	9.87e-06	0.00056	CbGpPWpGaD
Mifepristone—PGR—Gene Expression—MYC—sarcoma	9.41e-06	0.000534	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—ENO2—sarcoma	9.01e-06	0.000511	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—HBA1—sarcoma	8.95e-06	0.000508	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—MDM2—sarcoma	8.76e-06	0.000497	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—ENO2—sarcoma	8.49e-06	0.000481	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—HBA1—sarcoma	8.43e-06	0.000478	CbGpPWpGaD
Mifepristone—ABCC1—Disease—MDM2—sarcoma	8.17e-06	0.000463	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—IL2—sarcoma	7.83e-06	0.000444	CbGpPWpGaD
Mifepristone—ABCB1—Metabolism—PLCG1—sarcoma	7.64e-06	0.000433	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CCND1—sarcoma	7.63e-06	0.000433	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—JUN—sarcoma	7.62e-06	0.000432	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—CTNNB1—sarcoma	7.56e-06	0.000429	CbGpPWpGaD
Mifepristone—CYP2D6—Metabolism—PLCG1—sarcoma	7.2e-06	0.000408	CbGpPWpGaD
Mifepristone—AR—Gene Expression—MYC—sarcoma	7.17e-06	0.000407	CbGpPWpGaD
Mifepristone—ABCC1—Disease—CTNNB1—sarcoma	7.04e-06	0.0004	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—SRC—sarcoma	6.83e-06	0.000387	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—VEGFA—sarcoma	6.65e-06	0.000377	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—NRAS—sarcoma	6.57e-06	0.000373	CbGpPWpGaD
Mifepristone—ABCC1—Disease—SRC—sarcoma	6.37e-06	0.000361	CbGpPWpGaD
Mifepristone—ABCC1—Disease—NRAS—sarcoma	6.13e-06	0.000347	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—MYC—sarcoma	6.12e-06	0.000347	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—EGFR—sarcoma	5.99e-06	0.00034	CbGpPWpGaD
Mifepristone—ABCC1—Disease—MYC—sarcoma	5.71e-06	0.000324	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—KRAS—sarcoma	5.66e-06	0.000321	CbGpPWpGaD
Mifepristone—ABCC1—Disease—EGFR—sarcoma	5.58e-06	0.000317	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—ENO2—sarcoma	5.55e-06	0.000315	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—HBA1—sarcoma	5.51e-06	0.000313	CbGpPWpGaD
Mifepristone—NR3C1—Gene Expression—MYC—sarcoma	5.44e-06	0.000309	CbGpPWpGaD
Mifepristone—ABCC1—Disease—KRAS—sarcoma	5.27e-06	0.000299	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—TP53—sarcoma	5.03e-06	0.000285	CbGpPWpGaD
Mifepristone—PGR—Signaling Pathways—HRAS—sarcoma	4.81e-06	0.000273	CbGpPWpGaD
Mifepristone—CYP3A4—Metabolism—PLCG1—sarcoma	4.71e-06	0.000267	CbGpPWpGaD
Mifepristone—ABCC1—Disease—HRAS—sarcoma	4.48e-06	0.000254	CbGpPWpGaD
